Oramed to Present at Jefferies Global Healthcare Conference on June 2 in New York City

 Oramed to Present at Jefferies Global Healthcare Conference on June 2 in New
                                  York City

PR Newswire

JERUSALEM, May 27, 2014

JERUSALEM, May 27, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM:
ORMP) (www.oramed.com),a clinical-stage pharmaceutical company focused on the
development of oral drug delivery systems, announced today that Nadav Kidron,
the Company's Chief Executive Officer, will deliver a corporate presentation
at the Jefferies Global Healthcare Conference taking place from June 2-5,
2014, in New York City.

Presentation Details

Jefferies Global Healthcare Conference
Date: Monday, June 2, 2014
Time: 9:30am EDT

A live webcast of the presentation can be viewed at
http://wsw.com/webcast/jeff82/ORMP and will be archived for an additional 90
days.

About The Jefferies Global Healthcare Conference

The conference will feature an extensive range of public & private healthcare
companies across the biopharmaceuticals, life sciences, healthcare services,
healthcare IT and medical technology sectors. This global gathering of leading
executives, institutional investors, private equity investors and VCs will
address near- and long-term investment opportunities and discuss the
mechanisms driving healthcare in the U.S. and internationally. The four- day
conference will be comprised of company presentations, Q&A breakout sessions,
keynotes and thematic panels. Company management teams and investors will also
have the opportunity to participate in 1x1 and small group meetings.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs currently delivered via injection. Established in 2006,
Oramed's Protein Oral Delivery (POD^TM) technology is based on over 30 years
of research by top research scientists at Jerusalem'sHadassah Medical Center.
Oramed is seeking to revolutionize the treatment of diabetes through its
proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801)
currently in separate Phase II clinical trials in patients with both type 1
and type 2 diabetes under an Investigational New Drug application with the
U.S. FDA, and with its oral GLP-1 analog capsule (ORMD-0901) entering
IND-enabling studies later this year.

For more information, the content of which is not part of this press release,
please visit:  www.oramed.com

Forward-looking statements: This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 and other federal securities laws. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates" and
similar expressions or variations of such words are intended to identify
forward-looking statements. For example, we are using forward-looking
statements when we discuss our clinical trials, including the expected design
or timing thereof and revolutionizing the treatment of diabetes with our
products. These forward-looking statements are based on the current
expectations of the management of Oramed only, and are subject to a number of
factors and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements, including the risks
and uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product candidates;
competition from other pharmaceutical or biotechnology companies; and our
ability to obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the following
factors, among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in technology and
market requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our technology
as we progress further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen scientific
difficulties that may develop with our process; greater cost of final product
than anticipated; loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally good results
in real settings; our patents may not be sufficient; and final that products
may harm recipients, all of which could cause the actual results or
performance of Oramed to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Oramed
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:                                    US Investor Relations
Oramed Pharmaceuticals            Contact:
Aviva Guiloff
                                                    LifeSci Advisors LLC
Office: +972-2-566-0001 ext. 2
                                                    Andrew McDonald
US: 1-718-831-2512 ext. 2
                                                    US: 1-646-597-6987
Email: aviva@oramed.com                            Email:
                                                    andrew@lifesciadvisors.com

SOURCE Oramed Pharmaceuticals Inc.

Website: http://www.oramed.com
 
Press spacebar to pause and continue. Press esc to stop.